Pulse methylprednisolone treatment of idiopathic steroid-resistant nephrotic syndrome

P. D. Yorgin, Judy Krasher, Amira Al-Uzri

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Although much of the interest in pulse methylprednisolone therapy (PMT) has centered around its use in children with focal segmental glomerulosclerosis, PMT has also been shown to be effective in the treatment of other proteinuric renal diseases. We hypothesized that a PMT-based treatment protocol, derived from the Tune-Mendoza protocol, would effectively induce a more rapid remission in young children with idiopathic steroid-resistant nephrotic syndrome (SRNS). A retrospective analysis was conducted of 11 consecutive SRNS patients (mean age 3.6±1.5 years) that received PMT between 1 August 1992 and 1 May 1998. The initial mean urinary protein/urinary creatinine ratio (UP/UC, mg/mg) was 8.3±9.7 and mean estimated creatinine clearance (CCr) 137.7±47.0 ml/min per 1.73 m2. An average of 24.8±10.5 PMT doses were given. The mean duration of PMT therapy until remission was 23.4±29.9 days (median 12 days). Cyclosporine and cyclophosphamide were used to maintain and extend remissions in 5 and 4 patients, respectively. At the conclusion of the study, the mean UP/UC was 0.12±0.22 and mean CCr 151.8± 39.8 ml/min per 1.73 m2 (no CCr≤100 ml/min per 1.73m2). Of the 11 patients, 9 attained complete remission. Adverse effects were mild and infrequent. This PMT protocol appears to safely and effectively induce remission in young children with SRNS. A future prospective trial that evaluates the efficacy of PMT in young children with SRNS is warranted.

Original languageEnglish (US)
Pages (from-to)245-250
Number of pages6
JournalPediatric Nephrology
Volume16
Issue number3
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Methylprednisolone
Nephrotic Syndrome
Therapeutics
Creatinine
Steroids
Nephrotic syndrome, idiopathic, steroid-resistant
Focal Segmental Glomerulosclerosis
Clinical Protocols
Cyclophosphamide
Cyclosporine
Kidney

Keywords

  • Complications
  • Corticosteroids
  • Creatinine clearance
  • Cyclophosphamide
  • Cyclosporine
  • Minimal change disease
  • Proteinuria

ASJC Scopus subject areas

  • Nephrology
  • Pediatrics, Perinatology, and Child Health

Cite this

Pulse methylprednisolone treatment of idiopathic steroid-resistant nephrotic syndrome. / Yorgin, P. D.; Krasher, Judy; Al-Uzri, Amira.

In: Pediatric Nephrology, Vol. 16, No. 3, 2001, p. 245-250.

Research output: Contribution to journalArticle

@article{5a7e1b7886894ebea7dc33920b7a0b86,
title = "Pulse methylprednisolone treatment of idiopathic steroid-resistant nephrotic syndrome",
abstract = "Although much of the interest in pulse methylprednisolone therapy (PMT) has centered around its use in children with focal segmental glomerulosclerosis, PMT has also been shown to be effective in the treatment of other proteinuric renal diseases. We hypothesized that a PMT-based treatment protocol, derived from the Tune-Mendoza protocol, would effectively induce a more rapid remission in young children with idiopathic steroid-resistant nephrotic syndrome (SRNS). A retrospective analysis was conducted of 11 consecutive SRNS patients (mean age 3.6±1.5 years) that received PMT between 1 August 1992 and 1 May 1998. The initial mean urinary protein/urinary creatinine ratio (UP/UC, mg/mg) was 8.3±9.7 and mean estimated creatinine clearance (CCr) 137.7±47.0 ml/min per 1.73 m2. An average of 24.8±10.5 PMT doses were given. The mean duration of PMT therapy until remission was 23.4±29.9 days (median 12 days). Cyclosporine and cyclophosphamide were used to maintain and extend remissions in 5 and 4 patients, respectively. At the conclusion of the study, the mean UP/UC was 0.12±0.22 and mean CCr 151.8± 39.8 ml/min per 1.73 m2 (no CCr≤100 ml/min per 1.73m2). Of the 11 patients, 9 attained complete remission. Adverse effects were mild and infrequent. This PMT protocol appears to safely and effectively induce remission in young children with SRNS. A future prospective trial that evaluates the efficacy of PMT in young children with SRNS is warranted.",
keywords = "Complications, Corticosteroids, Creatinine clearance, Cyclophosphamide, Cyclosporine, Minimal change disease, Proteinuria",
author = "Yorgin, {P. D.} and Judy Krasher and Amira Al-Uzri",
year = "2001",
doi = "10.1007/s004670000494",
language = "English (US)",
volume = "16",
pages = "245--250",
journal = "Pediatric Nephrology",
issn = "0931-041X",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Pulse methylprednisolone treatment of idiopathic steroid-resistant nephrotic syndrome

AU - Yorgin, P. D.

AU - Krasher, Judy

AU - Al-Uzri, Amira

PY - 2001

Y1 - 2001

N2 - Although much of the interest in pulse methylprednisolone therapy (PMT) has centered around its use in children with focal segmental glomerulosclerosis, PMT has also been shown to be effective in the treatment of other proteinuric renal diseases. We hypothesized that a PMT-based treatment protocol, derived from the Tune-Mendoza protocol, would effectively induce a more rapid remission in young children with idiopathic steroid-resistant nephrotic syndrome (SRNS). A retrospective analysis was conducted of 11 consecutive SRNS patients (mean age 3.6±1.5 years) that received PMT between 1 August 1992 and 1 May 1998. The initial mean urinary protein/urinary creatinine ratio (UP/UC, mg/mg) was 8.3±9.7 and mean estimated creatinine clearance (CCr) 137.7±47.0 ml/min per 1.73 m2. An average of 24.8±10.5 PMT doses were given. The mean duration of PMT therapy until remission was 23.4±29.9 days (median 12 days). Cyclosporine and cyclophosphamide were used to maintain and extend remissions in 5 and 4 patients, respectively. At the conclusion of the study, the mean UP/UC was 0.12±0.22 and mean CCr 151.8± 39.8 ml/min per 1.73 m2 (no CCr≤100 ml/min per 1.73m2). Of the 11 patients, 9 attained complete remission. Adverse effects were mild and infrequent. This PMT protocol appears to safely and effectively induce remission in young children with SRNS. A future prospective trial that evaluates the efficacy of PMT in young children with SRNS is warranted.

AB - Although much of the interest in pulse methylprednisolone therapy (PMT) has centered around its use in children with focal segmental glomerulosclerosis, PMT has also been shown to be effective in the treatment of other proteinuric renal diseases. We hypothesized that a PMT-based treatment protocol, derived from the Tune-Mendoza protocol, would effectively induce a more rapid remission in young children with idiopathic steroid-resistant nephrotic syndrome (SRNS). A retrospective analysis was conducted of 11 consecutive SRNS patients (mean age 3.6±1.5 years) that received PMT between 1 August 1992 and 1 May 1998. The initial mean urinary protein/urinary creatinine ratio (UP/UC, mg/mg) was 8.3±9.7 and mean estimated creatinine clearance (CCr) 137.7±47.0 ml/min per 1.73 m2. An average of 24.8±10.5 PMT doses were given. The mean duration of PMT therapy until remission was 23.4±29.9 days (median 12 days). Cyclosporine and cyclophosphamide were used to maintain and extend remissions in 5 and 4 patients, respectively. At the conclusion of the study, the mean UP/UC was 0.12±0.22 and mean CCr 151.8± 39.8 ml/min per 1.73 m2 (no CCr≤100 ml/min per 1.73m2). Of the 11 patients, 9 attained complete remission. Adverse effects were mild and infrequent. This PMT protocol appears to safely and effectively induce remission in young children with SRNS. A future prospective trial that evaluates the efficacy of PMT in young children with SRNS is warranted.

KW - Complications

KW - Corticosteroids

KW - Creatinine clearance

KW - Cyclophosphamide

KW - Cyclosporine

KW - Minimal change disease

KW - Proteinuria

UR - http://www.scopus.com/inward/record.url?scp=0035098540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035098540&partnerID=8YFLogxK

U2 - 10.1007/s004670000494

DO - 10.1007/s004670000494

M3 - Article

C2 - 11322372

AN - SCOPUS:0035098540

VL - 16

SP - 245

EP - 250

JO - Pediatric Nephrology

JF - Pediatric Nephrology

SN - 0931-041X

IS - 3

ER -